• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: The Role of Salvage Surgery in Multidisciplinary Treatment for Unresectable Advanced Hepatocellular Carcinoma.

作者信息

Karasuyama Takuma, Ishii Takamichi, Yoh Tomoaki, Ogiso Satoshi, Takeda Haruhiko, Takai Atsushi, Kishi Noriko, Shimizu Hironori, Ito Takashi, Haga Hironori, Hatano Etsuro

机构信息

Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Ann Surg Oncol. 2025 Mar;32(3):1837-1838. doi: 10.1245/s10434-024-16719-2. Epub 2024 Dec 12.

DOI:10.1245/s10434-024-16719-2
PMID:39666190
Abstract
摘要

相似文献

1
ASO Author Reflections: The Role of Salvage Surgery in Multidisciplinary Treatment for Unresectable Advanced Hepatocellular Carcinoma.ASO作者反思：挽救性手术在不可切除的晚期肝细胞癌多学科治疗中的作用
Ann Surg Oncol. 2025 Mar;32(3):1837-1838. doi: 10.1245/s10434-024-16719-2. Epub 2024 Dec 12.
2
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?ASO作者反思：转化治疗后不可切除肝细胞癌挽救性手术的影响：是否应推荐？
Ann Surg Oncol. 2024 May;31(5):3100-3101. doi: 10.1245/s10434-024-14991-w. Epub 2024 Feb 1.
3
ASO Author Reflections: Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma.ASO作者反思：最初不可切除的局部晚期T4食管鳞状细胞癌挽救性食管切除术的合适候选人
Ann Surg Oncol. 2020 Sep;27(9):3171-3172. doi: 10.1245/s10434-020-08441-6. Epub 2020 Apr 8.
4
ASO Author Reflections: Salvage Liver Transplant for Recurrent Hepatocellular Carcinoma After Treatments With Curative Intent.ASO作者反思：根治性治疗后复发性肝细胞癌的挽救性肝移植
Ann Surg Oncol. 2018 Dec;25(Suppl 3):794-795. doi: 10.1245/s10434-018-6960-1. Epub 2018 Oct 30.
5
ASO Author Reflections: How Should the Patients with Locally Advanced Unresectable Esophageal Cancer Be Treated with Multidisciplinary Approach?ASO作者反思：局部晚期不可切除食管癌患者应如何采用多学科方法进行治疗？
Ann Surg Oncol. 2020 Feb;27(2):468-469. doi: 10.1245/s10434-019-08030-2. Epub 2019 Nov 4.
6
ASO Author Reflections: Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.ASO作者反思：经动脉化疗栓塞的临床疗效与安全性：肝动脉灌注化疗联合酪氨酸激酶抑制剂，联合或不联合程序性细胞死亡蛋白1抑制剂治疗不可切除肝细胞癌的回顾性研究
Ann Surg Oncol. 2024 Nov;31(12):7902-7903. doi: 10.1245/s10434-024-16049-3. Epub 2024 Aug 13.
7
ASO Author Reflections: Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.ASO作者反思：局部晚期不可切除食管鳞状细胞癌的转化治疗
Ann Surg Oncol. 2023 Feb;30(2):871-872. doi: 10.1245/s10434-022-12776-7. Epub 2022 Nov 15.
8
ASO Author Reflections: Insights in Salvage Surgery for Esophageal Carcinoma.ASO作者反思：食管癌挽救性手术的见解
Ann Surg Oncol. 2025 Apr;32(4):2700-2701. doi: 10.1245/s10434-024-16653-3. Epub 2024 Dec 4.
9
Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability.不可切除肝细胞癌降期后的挽救性手术——一种提高可切除性的策略
Ann Surg Oncol. 2007 Dec;14(12):3301-9. doi: 10.1245/s10434-007-9549-7. Epub 2007 Sep 22.
10
ASO Author Reflections: Salvage Surgery for Anal Cancer.《美国外科医师学会（ASO）作者反思：肛管癌的挽救性手术》
Ann Surg Oncol. 2018 Dec;25(Suppl 3):852-853. doi: 10.1245/s10434-018-7025-1. Epub 2018 Nov 9.

本文引用的文献

1
Aggressive Multidisciplinary Treatment for Unresectable Hepatocellular Carcinoma: The Achievement of a Pathologic Complete Response and Long-Term Survival.不可切除肝细胞癌的积极多学科治疗：病理完全缓解及长期生存的实现
Ann Surg Oncol. 2025 Mar;32(3):1819-1820. doi: 10.1245/s10434-024-16622-w. Epub 2024 Dec 13.
2
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.使用阿替利珠单抗联合贝伐单抗治疗肝细胞癌时向转化治疗转变的预测因素。
Liver Int. 2024 Jun;44(6):1456-1463. doi: 10.1111/liv.15907. Epub 2024 Mar 15.
3
Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
RACB 研究方案：一项多中心、单臂、前瞻性研究，旨在评估阿替利珠单抗联合贝伐珠单抗治疗初始不可切除肝细胞癌的疗效。
BMC Cancer. 2023 Aug 21;23(1):780. doi: 10.1186/s12885-023-11302-6.
4
Left-sided major hepatectomy with en bloc resection of the hepatoduodenal ligament utilizing a liver-transection first approach: A video vignette.左半肝切除术联合肝十二指肠韧带整块切除术采用肝离断优先入路：视频病例
Asian J Surg. 2024 Jan;47(1):497-498. doi: 10.1016/j.asjsur.2023.04.071. Epub 2023 Apr 25.
5
Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy.纳入肝动脉灌注化疗的伴有下腔静脉瘤栓的肝细胞癌手术切除选择标准的建议
Surgery. 2017 Oct;162(4):742-751. doi: 10.1016/j.surg.2017.05.011. Epub 2017 Jul 10.